▶ 調査レポート

抗感染症薬のグローバル市場(2023年-2031年):抗菌薬、抗ウイルス薬、抗真菌薬、その他

• 英文タイトル:Anti-Infective Drugs Market (Drug Class: Antibacterials, Antivirals, Antifungals, and Others; and Route of Administration: Oral, Parenteral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが調査・発行した産業分析レポートです。抗感染症薬のグローバル市場(2023年-2031年):抗菌薬、抗ウイルス薬、抗真菌薬、その他 / Anti-Infective Drugs Market (Drug Class: Antibacterials, Antivirals, Antifungals, and Others; and Route of Administration: Oral, Parenteral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 / MRC2309A101資料のイメージです。• レポートコード:MRC2309A101
• 出版社/出版日:Transparency Market Research / 2023年7月31日
• レポート形態:英文、PDF、190ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥869,250 (USD5,795)▷ お問い合わせ
  Multi User¥1,319,250 (USD8,795)▷ お問い合わせ
  Corporate License¥1,769,250 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
抗感染症薬市場 - レポートの範囲TMRの調査レポート「世界の抗感染症薬市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るため、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界の抗感染症薬市場の収益を提供します。また、2023年から2031年までの世界の抗感染症薬市場の複合年間成長率(CAGR %)も掲載しています。

本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、抗感染症薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照しました。

二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体なども含まれます。アナリストはトップダウンアプローチとボトムアップアプローチを組み合わせて、世界の抗感染症薬市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界の抗感染症薬市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場プレイヤーだけでなく、世界の抗感染症薬市場への参入に関心のある企業にとっても貴重なツールとなります。

本レポートでは、世界の抗感染症薬市場の競争環境について掘り下げています。世界の抗感染症薬市場で事業を展開する主要企業を特定し、各企業を様々な属性でプロファイルしています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の抗感染症薬市場におけるプレイヤーの属性です。

抗感染症薬の世界市場レポートが回答した主要な質問
- 予測期間中の全地域における抗感染症薬の売上高/売上収益は?
- 世界の抗感染症薬市場におけるビジネスチャンスは?
- 市場における主な促進要因、阻害要因、機会、脅威とは?
- 予測期間中に最も速いCAGRで拡大する地域市場は?
- 2031年に世界で最も高い収益を上げると予測されるセグメントは?
- 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは?
- 世界市場で事業を展開する各企業の市場ポジションは?

抗感染症薬市場 - 調査目的と調査アプローチ
世界の抗感染症薬市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーと流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。

本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフと表を適切に配置した網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化することで、読者に視覚的に訴えかけます。また、過去と予測期間末の主要セグメントの市場シェアの比較も可能です。

本レポートでは、世界の抗感染症薬市場を製品、エンドユーザー、地域の観点から分析。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の抗感染症薬市場への投資について十分な情報に基づいたビジネス上の意思決定を行うことができます。

1. 序論
2. 仮定・調査方法
3. エグゼクティブサマリー
4. 市場概要
5. 主要インサイト
6. 抗感染症薬の世界市場分析&予測:薬効クラス別
7. 抗感染症薬の世界市場分析&予測:投与経路別
8. 抗感染症薬の世界市場分析&予測:疾患別
9. 抗感染症薬の世界市場分析&予測:流通チャネル別
10. 抗感染症薬の世界市場分析&予測:地域別
11. 北米の抗感染症薬市場の分析&予測
12. ヨーロッパの抗感染症薬市場の分析&予測
13. アジア太平洋地域の抗感染症薬市場の分析&予測
14. 中南米の抗感染症薬市場の分析&予測
15. 中東・アフリカの抗感染症薬市場の分析&予測
16. 競争状況

レポート目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anti-infective Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Anti-infective Drugs Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Disease Prevalence & Incidence Rate Globally With Key Countries
    5.2. Regulatory Scenario, by Region
    5.3. Reimbursement Scenario by Region/Globally
    5.4. Pipeline Analysis
    5.5. Key Product/Brand Analysis
    5.6. Key Mergers & Acquisitions
    5.7. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)
6. Global Anti-infective Drugs Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2017-2031
        6.3.1. Antibacterials
            6.3.1.1. B-lactams
            6.3.1.2. Quinolones
            6.3.1.3. Macrolides
            6.3.1.4. Tetracycline
            6.3.1.5. Aminoglycoside
            6.3.1.6. Others
        6.3.2. Antivirals
            6.3.2.1. Miscellaneous Antivirals
            6.3.2.2. Adamantane Antivirals
            6.3.2.3. Antiviral Boosters
            6.3.2.4. Others
        6.3.3. Antifungals
            6.3.3.1. Azoles
            6.3.3.2. Echinocandins
            6.3.3.3. Polyenes
            6.3.3.4. Others
        6.3.4. Others
    6.4. Market Attractiveness Analysis, by Drug Class
7. Global Anti-infective Drugs Market Analysis and Forecast, by Route of Administration
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Route of Administration, 2017-2031
        7.3.1. Oral
        7.3.2. Parenteral
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Anti-infective Drugs Market Analysis and Forecast, by Indication
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Indication, 2017-2031
        8.3.1. Pneumonia
        8.3.2. Sepsis
        8.3.3. Tuberculosis
        8.3.4. Influenza
        8.3.5. HIV Infection
        8.3.6. Hepatitis Virus Infection
        8.3.7. Respiratory Virus Infection
        8.3.8. Others
    8.4. Market Attractiveness Analysis, by Indication
9. Global Anti-infective Drugs Market Analysis and Forecast, by Distribution Channel
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Distribution Channel, 2017-2031
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness Analysis, by Distribution Channel
10. Global Anti-infective Drugs Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness By Country/Region
11. North America Anti-infective Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017-2031
        11.2.1. Antibacterials
            11.2.1.1. B-lactams
            11.2.1.2. Quinolones
            11.2.1.3. Macrolides
            11.2.1.4. Tetracycline
            11.2.1.5. Aminoglycoside
            11.2.1.6. Others
        11.2.2. Antivirals
            11.2.2.1. Miscellaneous Antivirals
            11.2.2.2. Adamantane Antivirals
            11.2.2.3. Antiviral Boosters
            11.2.2.4. Others
        11.2.3. Antifungals
            11.2.3.1. Azoles
            11.2.3.2. Echinocandins
            11.2.3.3. Polyenes
            11.2.3.4. Others
        11.2.4. Others
    11.3. Market Value Forecast, by Route of Administration, 2017-2031
        11.3.1. Oral
        11.3.2. Parenteral
        11.3.3. Others
    11.4. Market Value Forecast, by Indication, 2017-2031
        11.4.1. Pneumonia
        11.4.2. Sepsis
        11.4.3. Tuberculosis
        11.4.4. Influenza
        11.4.5. HIV Infection
        11.4.6. Hepatitis Virus Infection
        11.4.7. Respiratory Virus Infection
        11.4.8. Others
    11.5. Market Value Forecast, by Distribution Channel, 2017-2031
        11.5.1. Hospital Pharmacies
        11.5.2. Retail Pharmacies
        11.5.3. Online Pharmacies
    11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Drug Class
        11.7.2. By Route of Administration
        11.7.3. By Indication
        11.7.4. By Distribution Channel
        11.7.5. By Country/Sub-region
12. Europe Anti-infective Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017-2031
        12.2.1. Antibacterials
            12.2.1.1. B-lactams
            12.2.1.2. Quinolones
            12.2.1.3. Macrolides
            12.2.1.4. Tetracycline
            12.2.1.5. Aminoglycoside
            12.2.1.6. Others
        12.2.2. Antivirals
            12.2.2.1. Miscellaneous Antivirals
            12.2.2.2. Adamantane Antivirals
            12.2.2.3. Antiviral Boosters
            12.2.2.4. Others
        12.2.3. Antifungals
            12.2.3.1. Azoles
            12.2.3.2. Echinocandins
            12.2.3.3. Polyenes
            12.2.3.4. Others
        12.2.4. Others
    12.3. Market Value Forecast, by Route of Administration, 2017-2031
        12.3.1. Oral
        12.3.2. Parenteral
        12.3.3. Others
    12.4. Market Value Forecast, by Indication, 2017-2031
        12.4.1. Pneumonia
        12.4.2. Sepsis
        12.4.3. Tuberculosis
        12.4.4. Influenza
        12.4.5. HIV Infection
        12.4.6. Hepatitis Virus Infection
        12.4.7. Respiratory Virus Infection
        12.4.8. Others
    12.5. Market Value Forecast, by Distribution Channel, 2017-2031
        12.5.1. Hospital Pharmacies
        12.5.2. Retail Pharmacies
        12.5.3. Online Pharmacies
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Drug Class
        12.7.2. By Route of Administration
        12.7.3. By Indication
        12.7.4. By Distribution Channel
        12.7.5. By Country/Sub-region
13. Asia Pacific Anti-infective Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017-2031
        13.2.1. Antibacterials
            13.2.1.1. B-lactams
            13.2.1.2. Quinolones
            13.2.1.3. Macrolides
            13.2.1.4. Tetracycline
            13.2.1.5. Aminoglycoside
            13.2.1.6. Others
        13.2.2. Antivirals
            13.2.2.1. Miscellaneous Antivirals
            13.2.2.2. Adamantane Antivirals
            13.2.2.3. Antiviral Boosters
            13.2.2.4. Others
        13.2.3. Antifungals
            13.2.3.1. Azoles
            13.2.3.2. Echinocandins
            13.2.3.3. Polyenes
            13.2.3.4. Others
        13.2.4. Others
    13.3. Market Value Forecast, by Route of Administration, 2017-2031
        13.3.1. Oral
        13.3.2. Parenteral
        13.3.3. Others
    13.4. Market Value Forecast, by Indication, 2017-2031
        13.4.1. Pneumonia
        13.4.2. Sepsis
        13.4.3. Tuberculosis
        13.4.4. Influenza
        13.4.5. HIV Infection
        13.4.6. Hepatitis Virus Infection
        13.4.7. Respiratory Virus Infection
        13.4.8. Others
    13.5. Market Value Forecast, by Distribution Channel, 2017-2031
        13.5.1. Hospital Pharmacies
        13.5.2. Retail Pharmacies
        13.5.3. Online Pharmacies
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. India
        13.6.3. Japan
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Drug Class
        13.7.2. By Route of Administration
        13.7.3. By Indication
        13.7.4. By Distribution Channel
        13.7.5. By Country/Sub-region
14. Latin America Anti-infective Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017-2031
        14.2.1. Antibacterials
            14.2.1.1. B-lactams
            14.2.1.2. Quinolones
            14.2.1.3. Macrolides
            14.2.1.4. Tetracycline
            14.2.1.5. Aminoglycoside
            14.2.1.6. Others
        14.2.2. Antivirals
            14.2.2.1. Miscellaneous Antivirals
            14.2.2.2. Adamantane Antivirals
            14.2.2.3. Antiviral Boosters
            14.2.2.4. Others
        14.2.3. Antifungals
            14.2.3.1. Azoles
            14.2.3.2. Echinocandins
            14.2.3.3. Polyenes
            14.2.3.4. Others
        14.2.4. Others
    14.3. Market Value Forecast, by Route of Administration, 2017-2031
        14.3.1. Oral
        14.3.2. Parenteral
        14.3.3. Others
    14.4. Market Value Forecast, by Indication, 2017-2031
        14.4.1. Pneumonia
        14.4.2. Sepsis
        14.4.3. Tuberculosis
        14.4.4. Influenza
        14.4.5. HIV Infection
        14.4.6. Hepatitis Virus Infection
        14.4.7. Respiratory Virus Infection
        14.4.8. Others
    14.5. Market Value Forecast, by Distribution Channel, 2017-2031
        14.5.1. Hospital Pharmacies
        14.5.2. Retail Pharmacies
        14.5.3. Online Pharmacies
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Drug Class
        14.7.2. By Route of Administration
        14.7.3. By Indication
        14.7.4. By Distribution Channel
        14.7.5. By Country/Sub-region
15. Middle East & Africa Anti-infective Drugs Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Drug Class, 2017-2031
        15.2.1. Antibacterials
            15.2.1.1. B-lactams
            15.2.1.2. Quinolones
            15.2.1.3. Macrolides
            15.2.1.4. Tetracycline
            15.2.1.5. Aminoglycoside
            15.2.1.6. Others
        15.2.2. Antivirals
            15.2.2.1. Miscellaneous Antivirals
            15.2.2.2. Adamantane Antivirals
            15.2.2.3. Antiviral Boosters
            15.2.2.4. Others
        15.2.3. Antifungals
            15.2.3.1. Azoles
            15.2.3.2. Echinocandins
            15.2.3.3. Polyenes
            15.2.3.4. Others
        15.2.4. Others
    15.3. Market Value Forecast, by Route of Administration, 2017-2031
        15.3.1. Oral
        15.3.2. Parenteral
        15.3.3. Others
    15.4. Market Value Forecast, by Indication, 2017-2031
        15.4.1. Pneumonia
        15.4.2. Sepsis
        15.4.3. Tuberculosis
        15.4.4. Influenza
        15.4.5. HIV Infection
        15.4.6. Hepatitis Virus Infection
        15.4.7. Respiratory Virus Infection
        15.4.8. Others
    15.5. Market Value Forecast, by Distribution Channel, 2017-2031
        15.5.1. Hospital Pharmacies
        15.5.2. Retail Pharmacies
        15.5.3. Online Pharmacies
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Drug Class
        15.7.2. By Route of Administration
        15.7.3. By Indication
        15.7.4. By Distribution Channel
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (by Tier and Size of Companies)
    16.2. Market Share Analysis, by Company, 2022
    16.3. Company Profiles
        16.3.1. Pfizer Inc.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Gland Pharma Ltd.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Teva Pharmaceutical Industries Ltd.
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. F. Hoffmann-La Roche Ltd.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Novartis AG
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. GlaxoSmithKline plc
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. Gilead Sciences, Inc.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Merck & Co., Inc.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Abbott
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Astellas Pharma Inc.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Alkem Laboratories
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. AstraZeneca
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview
        16.3.13. Eli Lilly and Company
            16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.13.2. Product Portfolio
            16.3.13.3. Financial Overview
            16.3.13.4. SWOT Analysis
            16.3.13.5. Strategic Overview
        16.3.14. Johnson & Johnson Services, Inc.
            16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.14.2. Product Portfolio
            16.3.14.3. Financial Overview
            16.3.14.4. SWOT Analysis
            16.3.14.5. Strategic Overview
        16.3.15. Takeda Pharmaceutical Company Limited
            16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.15.2. Product Portfolio
            16.3.15.3. Financial Overview
            16.3.15.4. SWOT Analysis
            16.3.15.5. Strategic Overview
        16.3.16. Sanofi
            16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.16.2. Product Portfolio
            16.3.16.3. Financial Overview
            16.3.16.4. SWOT Analysis
            16.3.16.5. Strategic Overview

List of Tables

Table 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 02: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031

Table 03: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031

Table 04: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031

Table 05: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 06: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 07: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 08: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 09: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 10: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031

Table 11: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031

Table 12: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031

Table 13: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 14: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 15: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 16: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 17: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 18: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031

Table 19: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031

Table 20: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031

Table 21: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 22: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 23: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 24: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 25: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 26: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031

Table 27: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031

Table 28: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031

Table 29: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 30: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 31: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 32: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 33: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 34: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031

Table 35: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031

Table 36: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031

Table 37: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 38: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 39: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 40: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 41: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031

Table 42: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031

Table 43: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031

Table 44: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031

Table 45: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 46: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 47: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 48: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031